The Groningen-based medtech and deeptech startup Sencilia has raised approximately €2 million to further develop its Rely-V® sensor technology. The funding round consists of investments from NOM, Future Tech Ventures (FTV), imec.istart, RUG Ventures, Triade, and private investors. In addition, Sencilia is receiving a grant through the European Eureka Eurostars program and an innovation loan from Rabobank.
“This investment will help us further develop our prototype toward production, collect more clinical data, and collaborate with manufacturers of infusion pumps and infusion sets. The investment also gives us the opportunity to grow further as a company. Groningen plays an important role in this: many team members started at Sencilia as students, interns, or through small projects,” says Amar Kamat, founder and CEO of Sencilia.
Making IV medication administration safer for babies and children
Especially when patients receive very small doses of medication, it can be difficult to detect problems with an IV in time. Sencilia’s smart sensor technology is designed to help healthcare providers identify such problems earlier, without requiring them to make significant changes to their workflow. Rely-V® is attached to the outside of a standard IV tubing and measures the actual flow rate—down to 0.1 milliliters per hour—without coming into contact with the medication.
The technology is initially being developed for the care of infants and children. These are vulnerable patients who often receive very small doses of medication. In the future, the technology could also be used for other applications in intravenous therapy.
Follow-on investment supports next phase of development
The NOM is the lead investor in this joint funding round. Sencilia’s potential impact on healthcare and the region were key reasons for the NOM to invest now. The NOM is acting as the lead investor in this investment round. The company’s potential impact on healthcare and the region were key reasons for the NOM to invest now.
“We’ve been following Sencilia’s development for about three years now, and it’s wonderful to see how much progress the company has made during that time,” says Parichita Chakraborty, Investment Manager for Life Sciences & Health at NOM. “Sencilia has developed a unique technology that can have a major impact on the lives of vulnerable patients, such as premature babies. The company offers a robust solution for a market with a clear need and has a skilled and resilient team. We’re happy to help Sencilia continue to grow.”
“Since Future Tech Ventures ’ initial investment in August 2025, Sencilia has made great strides. The company has further developed the technology, gained a better understanding of where it can make the biggest difference, and gained experience through trials with companies and healthcare professionals,” says Hilbrand van der Zee, Investment Manager at Future Tech Ventures. “With this follow-on investment, we’re giving Sencilia the leeway to continue that development and prepare the technology for use in healthcare.”
Sencilia previously participated in the imec.istart.nl accelerator program, which supports technology startups with early-stage investments, tailored guidance, and access to an international network of experts, partners, and investors. As an existing investor, imec.istart.nl is also supporting Sencilia in its next phase of growth.
From Groningen to international markets
Sencilia focuses on the European and U.S. markets and aims to form partnerships with international manufacturers of infusion pumps and infusion sets. If development and approval proceed as planned, the company expects the first products featuring the sensor technology to hit the market starting in 2028.